Eli Lilly suspends access to drug discounts for some hospitals

Eli Lilly has halted its drug discount program for certain safety-net hospitals, citing the need to root out waste, fraud, and abuse. To qualify for the discounts, hospitals must now provide insurance claims data for in-house pharmacy dispensing, a significant shift from previous practices. This move could affect patient care in low-income areas, where these hospitals play a crucial role, and it raises concerns about access to affordable medications for vulnerable populations. The decision underscores broader issues in pharmaceutical pricing and healthcare equity.